Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists Class 1 or 2 or 3~* \>=18 years of age and of either sex~* scheduled for elective surgical procedure under general anesthesia requiring the use of rocuronium for endotracheal intubation and/or maintenance of neuromuscular blockade in a supine position allowing neuromuscular transmission monitoring and requiring reversal of neuromuscular blockade~* Korean descent born in Korea, never emigrated out of Korea, and have a Korean home address~Exclusion Criteria:~* expected difficult intubation due to anatomic malformations~* expected transfer to intensive care unit after surgery~* neuromuscular disorders affecting neuromuscular blockade~* significant hepatic or renal dysfunction~* require use of pneumatic tourniquet during surgery~* (family) history of malignant hyperthermia~* allergy to cyclodextrins (including sugammadex) or other medication(s) used during general anesthesia; use of toremifene or fusidic acid within 24 hours of study drug administration; contraindication to use of neostigmine or glycopyrrolate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex (Type: EXPERIMENTAL): None
- Neostigmine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).